Dupilumab treatment for severe atopic dermatitis in children and SARS‐CoV‐2 infection: A combination of triggers for psoriasis.
- Resource Type
- Article
- Authors
- Colonna, Cristiana; Bortoluzzi, Paolo; Cavalli, Riccardo
- Source
- Journal of the European Academy of Dermatology & Venereology. May2023, Vol. 37 Issue 5, pe568-e569. 2p.
- Subject
- *ATOPIC dermatitis
*DUPILUMAB
*PSORIASIS
*SARS-CoV-2
*ITCHING
- Language
- ISSN
- 0926-9959
Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns. Dear Editor, Dupilumab was approved by European Medicine Agency (EMA) in 2020 for use in children aged 6-11 years with severe atopic dermatitis (AD). When initiating therapy with dupilumab the patient presented an Eczema Area and Severity Index (EASI) of 30, an Itch Numeric Rating Scale (NRS) of six and a Dermatology Life Quality Index (DLQI) of six. [Extracted from the article]